Prognostic Value of MammaPrint(®) in Invasive Lobular Breast Cancer

BACKGROUND: MammaPrint® is a microarray-based gene expression test cleared by the US Food and Drug Administration to assess recurrence risk in early-stage breast cancer, aimed to guide physicians in making neoadjuvant and adjuvant treatment decisions. The increase in the incidence of invasive lobula...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biomark Insights
Autors principals: Beumer, Inès J., Persoon, Marion, Witteveen, Anke, Dreezen, Christa, Chin, Suet-Feung, Sammut, Stephen-John, Snel, Mireille, Caldas, Carlos, Linn, Sabine, van ’t Veer, Laura J., Bernards, Rene, Glas, Annuska M.
Format: Artigo
Idioma:Inglês
Publicat: Libertas Academica 2016
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5153320/
https://ncbi.nlm.nih.gov/pubmed/27980389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/BMI.S38435
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars